Literature DB >> 11277563

Entorhinal cortex disruption causes memory deficit in early Alzheimer's disease as shown by PET.

F Eustache1, B Desgranges, B Giffard, V de la Sayette, J C Baron.   

Abstract

Voxel-based mapping of the correlations between cognitive scores and resting-state brain glucose utilization measured by PET has recently emerged as a novel way to reveal in living patients with Alzheimer's disease (AD) the neural systems whose disruption underlies particular neuropsychological, especially mnemonic, deficits. We have now applied this approach using a novel cognitive paradigm designed to selectively assess verbal episodic memory, and show that in early AD disruption of the left entorhinal cortex underlies this memory deficit, consistent with post mortem data showing that this brain area is affected earliest and most severely by tau pathology in AD.

Entities:  

Mesh:

Year:  2001        PMID: 11277563     DOI: 10.1097/00001756-200103260-00013

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  17 in total

1.  Episodic memory impairment in patients with Alzheimer's disease is correlated with entorhinal cortex atrophy. A voxel-based morphometry study.

Authors:  M Di Paola; E Macaluso; G A Carlesimo; F Tomaiuolo; K J Worsley; L Fadda; C Caltagirone
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

Review 2.  MNESIS: towards the integration of current multisystem models of memory.

Authors:  Francis Eustache; Béatrice Desgranges
Journal:  Neuropsychol Rev       Date:  2008-02-29       Impact factor: 7.444

3.  MRI signatures of brain macrostructural atrophy and microstructural degradation in frontotemporal lobar degeneration subtypes.

Authors:  Yu Zhang; Maria Carmela Tartaglia; Norbert Schuff; Gloria C Chiang; Christopher Ching; Howard J Rosen; Maria Luisa Gorno-Tempini; Bruce L Miller; Michael W Weiner
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: A study combining MRI and FDG-PET.

Authors:  M-S Buhour; F Doidy; M Laisney; A L Pitel; V de La Sayette; F Viader; F Eustache; B Desgranges
Journal:  Brain Imaging Behav       Date:  2017-02       Impact factor: 3.978

5.  Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease.

Authors:  Cheryl L Grady; Anthony R McIntosh; Sania Beig; Michelle L Keightley; Hana Burian; Sandra E Black
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

6.  Effects of medial temporal lobe degeneration on brain perfusion in amnestic MCI of AD type: deafferentation and functional compensation?

Authors:  Eric Guedj; Emmanuel J Barbeau; Mira Didic; Olivier Felician; Catherine de Laforte; Jean-Philippe Ranjeva; Michel Poncet; Patrick J Cozzone; Olivier Mundler; Mathieu Ceccaldi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-18       Impact factor: 9.236

7.  Entorhinal cortex structure and functional MRI response during an associative verbal memory task.

Authors:  Meredith N Braskie; Gary W Small; Susan Y Bookheimer
Journal:  Hum Brain Mapp       Date:  2009-12       Impact factor: 5.038

8.  Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.

Authors:  Christian Habeck; Shannon Risacher; Grace J Lee; M Maria Glymour; Elizabeth Mormino; Shubhabrata Mukherjee; Sungeun Kim; Kwangsik Nho; Charles DeCarli; Andrew J Saykin; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

Review 9.  [PET and SPECT investigations in Alzheimer's disease].

Authors:  S Asenbaum
Journal:  Radiologe       Date:  2003-06-25       Impact factor: 0.635

10.  Classifying late-onset dementia with MRI: is arteriosclerotic brain degeneration the most common cause of Alzheimer's syndrome?

Authors:  Marie Cécile Henry-Feugeas; Fannie Onen; Elisabeth Schouman Claeys
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.